inflammatory bowel disease
The Seattle-based company recently completed a strategic reorganization around its two major business areas by cutting the workforce and appointing a new CFO.
The Seattle-based company recently published immune repertoire data showing the potential of T-cell receptor profiling in IBD diagnostics.
Adaptive Biotechnologies to Focus on Immune Medicine, Minimal Residual Disease Testing Businesses
Premium
The Seattle-based company said this week that its immune medicine and minimal residual disease testing business arms will drive the firm's future growth.
Coral Genomics, Crohn's & Colitis Foundation Partner on Study of IBD Treatment Response
San Francisco-based Coral will study up to 1,000 patients in an IBD cohort as it develops a test to predict patient response to treatment.
Roche, Mimetas Partner to Develop Disease Models for Drug Discovery
The companies are doing research to characterize novel drug compounds in inflammatory bowel disease and hepatitis B virus.
Mar 12, 2021
Prometheus Biosciences Prices Upsized $190M IPO
Jul 13, 2020
Jul 30, 2019